The clinical application of linagliptin in Asians

References

• International Diabetes Federation Key findings 2014Diabetes Atlas6th edBrusselsInternational Diabetes Federation2014
   Google Scholar
• WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
   PubMed Web of Science ®Google Scholar
• ChanJCMalikVJiaWDiabetes in Asia: epidemiology, risk factors, and pathophysiologyJAMA2009301202129214019470990
   PubMed Web of Science ®Google Scholar
• KarterAJFerraraALiuJYMoffetHHAckersonLMSelbyJVEthnic disparities in diabetic complications in an insured populationJAMA2002287192519252712020332
   PubMed Web of Science ®Google Scholar
• FlynnCBakrisGLNoninsulin glucose-lowering agents for the treatment of patients on dialysisNat Rev Nephrol20139314715323358424
   PubMed Web of Science ®Google Scholar
• OwensDRSwallowRDugiKAWoerleHJEfficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized studyDiabet Med201128111352136121781152
   PubMed Web of Science ®Google Scholar
• GhaziTRinkLSherrJLHeroldKCAcute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challengesDiabetes Care201437121021623939544
   PubMed Web of Science ®Google Scholar
• ChiaCWEganJMIncretin-based therapies in type 2 diabetes mellitusJ Clin Endocrinol Metab200893103703371618628530
   PubMed Web of Science ®Google Scholar
• BaggerJIKnopFKLundAVestergaardHHolstJJVilsbollTImpaired regulation of the incretin effect in patients with type 2 diabetesJ Clin Endocrinol Metab201196373774521252240
   PubMed Web of Science ®Google Scholar
• AgrawalRJainPDikshitSNLinagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitorCurr Drug Targets201213797098322420306
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacokinetics of dipeptidylpeptidase-4 inhibitorsDiabetes Obes Metab201012864865820590741
   PubMed Web of Science ®Google Scholar
• ScottLJLinagliptin: in type 2 diabetes mellitusDrugs201171561162421443284
   PubMed Web of Science ®Google Scholar
• HorieYKanadaSWatadaHPharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patientsClin Ther201133797398921723606
   PubMed Web of Science ®Google Scholar
• SarashinaASesokoSNakashimaMLinagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjectsClin Ther20103261188120420637971
   PubMed Web of Science ®Google Scholar
• FriedrichCShiXZengPRingAWoerleHPatelSPharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteersInt J Clin Pharmacol Ther20125088989523073142
   PubMed Web of Science ®Google Scholar
• HeiseTGraefe-ModyEUHuttnerSRingATrommeshauserDDugiKAPharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patientsDiabetes Obes Metab200911878679419476474
   PubMed Web of Science ®Google Scholar
• Tradjenta® (linagliptin) tabletsHighlights of Prescribing Information2013
   Google Scholar
• FuchsHTillementJPUrienSGreischelARothWConcentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansJ Pharm Pharmacol2009611556219126297
   PubMed Web of Science ®Google Scholar
• TadayasuYSarashinaATsudaYPopulation pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitusJ Pharm Pharm Sci201316570872124393553
   PubMed Web of Science ®Google Scholar
• RetlichSDuvalVGraefe-ModyUJaehdeUStaabAImpact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patientsJ Clin Pharmacol201050887388520160157
   PubMed Web of Science ®Google Scholar
• HermanGAStevensCVan DyckKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther200578667568816338283
   PubMed Web of Science ®Google Scholar
• ThomasLEckhardtMLangkopfETadayyonMHimmelsbachFMarkM(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitorsJ Pharmacol Exp Ther2008325117518218223196
   PubMed Web of Science ®Google Scholar
• HuttnerSGraefe-ModyEUWithopfBRingADugiKASafety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteersJ Clin Pharmacol200848101171117818812608
   PubMed Web of Science ®Google Scholar
• DelPSBarnettAHHuismanHNeubacherDWoerleHJDugiKAEffect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes Obes Metab201113325826721205122
   PubMed Web of Science ®Google Scholar
• KawamoriRInagakiNArakiELinagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind studyDiabetes Obes Metab201214434835722145698
   PubMed Web of Science ®Google Scholar
• InagakiNWatadaHMuraiMLinagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetesDiabetes Obes Metab201315983384323565760
   PubMed Web of Science ®Google Scholar
• GallwitzBRosenstockJRauchT2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trialLancet2012380984047548322748821
   PubMed Web of Science ®Google Scholar
• HaakTMeinickeTJonesRWeberSvon EynattenMWoerleHJInitial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab201214656557422356132
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHRosenstockJDurán-GarciaSEffects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a >/=52-week randomized, double-blind studyDiabetes Care201336123875388124062327
   PubMed Web of Science ®Google Scholar
• BajajMGilmanRPatelSKempthorne-RawsonJLewis-D’AgostinoDWoerleHJLinagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind studyDiabet Med201431121505151424824197
   PubMed Web of Science ®Google Scholar
• ZengZYangJKTongNEfficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trialCurr Med Res Opin201329892192923672632
   PubMed Web of Science ®Google Scholar
• ZengZChoiDSMohanVEfficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysisCurr Med Res Opin20153119910625215428
   PubMed Web of Science ®Google Scholar
• BarnettAHPatelSHarperRLinagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extensionDiabetes Obes Metab201214121145115422974280
   PubMed Web of Science ®Google Scholar
• ArakiEKawamoriRInagakiNLong-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetesDiabetes Obes Metab201315436437123163910
   PubMed Web of Science ®Google Scholar
• TaskinenMRRosenstockJTamminenISafety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab2011131657421114605
   PubMed Web of Science ®Google Scholar
• GomisREspaderoRMJonesRWoerleHJDugiKAEfficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab201113765366121410628
   PubMed Web of Science ®Google Scholar
• ItoHAbeMAntokuSComparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment – retrospective observation study of Japanese patients with type 2 diabetes mellitusExpert Opin Pharmacother201516328929625529857
   PubMed Web of Science ®Google Scholar
• FriedrichCEmserAWoerleHJGraefe-ModyURenal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetesAm J Ther201320661862123411609
   PubMed Web of Science ®Google Scholar
• von EynattenMGongYEmserAWoerleHJEfficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trialsCardiovasc Diabetol2013126023570327
   PubMed Web of Science ®Google Scholar
• SanyalDGuptaSDasPA retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world settingIndian J Endocrinol Metab201317suppl 1S203S20524251159
   PubMedGoogle Scholar
• Graefe-ModyURosePRetlichSPharmacokinetics of linagliptin in subjects with hepatic impairmentBr J Clin Pharmacol2012741758522242621
   PubMed Web of Science ®Google Scholar
• LewinAJArvayLLiuDPatelSvon EynattenMWoerleHJEfficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trialClin Ther20123491909191922939034
   PubMed Web of Science ®Google Scholar
• International Diabetes FederationDiabetes Atlas6th edBrusselsInternational Diabetes Federation2013
   Google Scholar
• GujralUPPradeepaRWeberMBNarayanKMMohanVType 2 diabetes in South Asians: similarities and differences with white Caucasian and other populationsAnn N Y Acad Sci20131281516323317344
   PubMed Web of Science ®Google Scholar
• DECODA Study GroupInternational Diabetes Epidemiology GroupCardiovascular risk profile assessment in glucose-intolerant Asian individuals – an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia)Diabet Med200219754955712099957
   PubMed Web of Science ®Google Scholar
• CerielloACavarapeAMartinelliLThe postprandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspartDiabet Med200421217117514984453
   PubMed Web of Science ®Google Scholar
• StirbanAOTschoepeDCardiovascular complications in diabetes: targets and interventionsDiabetes Care200831suppl 2S215S22118227488
   PubMed Web of Science ®Google Scholar
• DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin200824102943295218786299
   PubMed Web of Science ®Google Scholar
• YamagishiSIshibashiYOjimaASugiuraTMatsuiTLinagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activityInt J Cardiol2014176255055225065332
   PubMed Web of Science ®Google Scholar
• AroorARSowersJRBenderSBDipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsEndocrinology201315472501251323653460
   PubMed Web of Science ®Google Scholar
• JohansenOENeubacherDvon EynattenMPatelSWoerleHJCardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programmeCardiovasc Diabetol201211322234149
   PubMed Web of Science ®Google Scholar
• JelsingJVrangNvan WitteloostuijnSBMarkMKleinTThe DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic miceJ Endocrinol2012214338138722761275
   PubMed Web of Science ®Google Scholar
• KimYGHahnSOhTJKwakSHParkKSChoYMDifferences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia201356469670823344728
   PubMed Web of Science ®Google Scholar
• KimSJNianCMcIntoshCHSitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathwaysDiabetes20105971739175020368408
   PubMed Web of Science ®Google Scholar
• TianLGaoJHaoJReversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitorEndocrinology201015173049306020444936
   PubMed Web of Science ®Google Scholar
• SarikondaGPettusJPhatakSCD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetesJ Autoimmun201450778224387802
   PubMed Web of Science ®Google Scholar
• ShahPArdestaniADharmadhikariGThe DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilizationJ Clin Endocrinol Metab2013987E1163E117223633194
   PubMed Web of Science ®Google Scholar
• YangWGuanYShentuYThe addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetesJ Diabetes20124322723722672586
   PubMed Web of Science ®Google Scholar
• PanCXingXHanPInstitution InvestigatorsEfficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitusDiabetes Obes Metab201214873774422369287
   PubMed Web of Science ®Google Scholar
• YangWPanCYTouCZhaoJGause-NilssonIEfficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trialDiabetes Res Clin Pract201194221722421871686
   PubMed Web of Science ®Google Scholar
• PanCYYangWTouCGause-NilssonIZhaoJEfficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trialDiabetes Metab Res Rev201228326827522081481
   PubMed Web of Science ®Google Scholar
• BoultonDWKasichayanulaSKeungCFSimultaneous oral therapeutic and intravenous (1)(4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozinBr J Clin Pharmacol201375376376822823746
   PubMed Web of Science ®Google Scholar
• PanchapakesanUPollockCADPP-4 inhibitors-renoprotection in diabetic nephropathy?Diabetes20146361829183024853893
   PubMed Web of Science ®Google Scholar
• Graefe-ModyUFriedrichCPortAEffect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin (*)Diabetes Obes Metab2011131093994621672124
   PubMed Web of Science ®Google Scholar
• GroopPHCooperMEPerkovicVEmserAWoerleHJvon EynattenMLinagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunctionDiabetes Care201336113460346824026560
   PubMed Web of Science ®Google Scholar
• KanasakiKShiSKanasakiMLinagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimenDiabetes20146362120213124574044
   PubMed Web of Science ®Google Scholar
• PanchapakesanUGrossSKomalaMGPeggKPollockCADPP4 inhibition in human kidney proximal tubular cells – renoprotection in diabetic nephropathy?J Diabetes Metab2013S9007
   Google Scholar
• NakashimaSMatsuiTTakeuchiMYamagishiSILinagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axisHorm Metab Res2014461071772124710699
   PubMed Web of Science ®Google Scholar
• LovshinJADruckerDJIncretin-based therapies for type 2 diabetes mellitusNat Rev Endocrinol20095526226919444259
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar